ArticleBMC microbiology2026
Rapid phenotypic antimicrobial susceptibility testing of Gram-negative bloodstream isolates: clinical evaluation of the LifeScale AST system.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBloodstream infections (BSIs) and sepsis require rapid initiation of appropriate antimicrobial therapy; however, conventional antimicrobial susceptibility testing (AST) methods are time-consuming and may delay targeted treatment. Rapid phenotypic AST performed directly from positive blood cultures may reduce time to effective therapy and support antimicrobial stewardship.
methodsThe analytical performance and turnaround time (TAT) and the time-to-result (TTR) of the LifeScale AST system were evaluated using monomicrobial Gram-negative organisms from positive blood cultures. A total of 156 adult blood culture isolates were tested in parallel using the LifeScale system and the standard-of-care (SoC) MicroScan WalkAway system. Performance was assessed across 14 antimicrobial agents using Essential agreement (EA), adjusted Categorical agreement (CA), and categorical error rates in accordance with Clinical and Laboratory Standards Institute (CLSI) 2025 breakpoints. Discrepant results were resolved by broth microdilution (BMD).
resultsAcross 1,360 organism-antimicrobial combinations, the LifeScale AST system demonstrated an overall EA of 97.72% and an adjusted CA of 95.81% following discrepancy resolution. No very major errors remained after adjudication; the final major and minor error rates were 0.37% and 3.90%, respectively. Median TAT was 8.6 h for the LifeScale system compared with 48.1 h for the SoC method, corresponding to a median reduction of 39.5 h and an approximately 80% decrease in TAT; the mean TTR was 4.2 h.
conclusionsThe LifeScale AST system demonstrated high analytical agreement with the SoC method while substantially reducing TAT for AST testing of Gram-negative bloodstream infection isolates. Rapid availability of reliable phenotypic susceptibility results directly from positive blood cultures may enable earlier optimization of antimicrobial therapy and support antimicrobial stewardship, particularly in the management of sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.